NASDAQ$HALO
Halozyme Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Halozyme's first quarter 2022 results were reported, showing revenue growth and increased earnings per share.
Halozyme reported a strong first quarter in 2022, with a 32% year-over-year increase in revenue, driven by record royalty revenues. The company also announced the pending acquisition of Antares Pharma, expected to boost long-term growth.
- First quarter revenue reached $117.3 million, a 32% increase year-over-year.
- GAAP diluted earnings per share were $0.43, and non-GAAP diluted earnings per share were $0.47.
- Record quarterly royalties of $69.6 million were achieved, representing an 89% increase over the first quarter of 2021.
- 2022 revenue guidance was reiterated at $530 million to $560 million, indicating a 20-26% growth over 2021.
Headline financials
Revenue & EPS history
Halozyme · Revenue · Quarterly
$117M
Revenue by segment
Halozyme · $95.1M total across 2 segments · Q1 2022
- Royalties$69.6M+88.5%73.2%
- Revenues under collaborative agreements$25.5M-15.8%26.8%
Forward guidance
The company reiterated its financial guidance for 2022, expecting total revenue between $530 million and $560 million and GAAP operating income between $350 million and $380 million.
Tailwinds
- Total revenue of $530 million to $560 million, representing growth of 20%-26% over 2021 total revenue.
- Revenue from royalties to increase approximately 50% over revenue from royalties in 2021 to approximately $300 million.
- GAAP operating income of $350 million to $380 million, representing growth of 27%-38% over 2021 GAAP operating income, resulting in operating margins greater than 65%.
- GAAP net income of $270 million to $295 million; and non-GAAP net income of $290 million to $315 million.
- GAAP diluted earnings per share of $1.90 to $2.05, inclusive of the first full year of income tax expense, projected to be $0.55-$0.60 per share.
Headwinds
- 2022 will be the first full fiscal year in which Halozyme will record income tax expense as part of its income statement.
- The company's financial guidance does not consider the impact of the potential Antares acquisition.
- The company's earnings per share guidance does not consider the impact of potential future share repurchases.
- Unexpected levels of revenues, expenditures and costs.
- Unexpected delays in the execution of the Company’s share repurchase program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+1.8%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+1.8%
Avg return
30 days after
62%
32 / 52 earnings
Positive
+18.2%
Q1 2025
Best reaction
-12.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +1.1% | +6.5% | |
| Q4 2025 | -9.0% | -12.2% | -21.2% | |
| Q3 2025 | +2.7% | +3.1% | -4.9% | |
| Q1 2025 | +18.2% | +12.1% | -8.6% | |
| Q3 2024 | +13.0% | +16.1% | -4.7% | |
| Q2 2024 | +3.9% | +5.9% | +17.2% | |
| Q1 2024 | +2.8% | +5.6% | +25.9% | |
| Q4 2023 | +6.3% | +12.4% | +11.4% | |
| Q3 2023 | +9.1% | +4.7% | +12.3% | |
| Q2 2023 | +1.5% | +4.1% | -6.8% | |
| Q1 2023 | +13.9% | +8.9% | +12.8% | |
| Q4 2022 | +0.1% | -1.0% | -32.7% | |
| Q3 2022 | +7.4% | +16.6% | +25.0% | |
| Q2 2022 | -2.1% | -4.2% | -11.9% | |
| Q1 2022 | +3.3% | +8.2% | +20.4% | |
| Q4 2021 | +3.1% | +8.6% | +18.3% | |
| Q3 2021 | +2.6% | +4.3% | -15.0% | |
| Q2 2021 | +1.8% | +2.4% | +3.8% | |
| Q1 2021 | -10.3% | -9.5% | -17.2% | |
| Q4 2020 | +5.7% | -7.1% | -15.2% | |
| Q3 2020 | +12.9% | +34.6% | +45.2% | |
| Q2 2020 | -2.7% | -3.7% | -3.2% | |
| Q1 2020 | +0.2% | +2.7% | -1.4% | |
| Q4 2019 | -4.7% | -10.4% | -22.4% | |
| Q3 2019 | +6.4% | +13.9% | +12.8% | |
| Q2 2019 | -0.9% | -5.1% | -5.3% | |
| Q1 2019 | -3.1% | -5.9% | -10.9% | |
| Q4 2018 | -0.4% | +1.8% | -8.2% | |
| Q3 2018 | +0.7% | +0.6% | -1.6% | |
| Q2 2018 | +0.3% | -2.6% | +2.5% | |
| Q1 2018 | -7.3% | -3.0% | -7.2% | |
| Q4 2017 | +3.8% | +7.2% | +9.9% | |
| Q3 2017 | +12.2% | +6.9% | +11.5% | |
| Q2 2017 | -4.0% | -9.7% | -0.7% | |
| Q1 2017 | -1.6% | +3.1% | -7.3% | |
| Q4 2016 | +0.2% | +5.6% | +1.2% | |
| Q3 2016 | +14.2% | +48.7% | +33.7% | |
| Q2 2016 | -0.4% | +1.6% | +6.2% | |
| Q1 2016 | +3.7% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | -12.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +1.1% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +1.7% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q3 2011 | -1.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | +5.2% | — | — | |
| Q1 2010 | -2.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro